Conv. Plasma
Nigella Sativa

All vitamin C studies
Meta analysis
study COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019

Xia et al., Nutrition, doi:10.1016/j.nut.2021.111405
Nov 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020
*, now known with p = 0.000000087 from 70 studies, recognized in 11 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective study of 236 hospitalized patients with severe COVID-19 in China. 85 patients received high-dose intravenous vitamin C (HIVC) along with standard care, 151 received standard care alone. Most patients showed signs of hyperinflammation based on elevated inflammatory marker levels. After treatment, inflammatory marker levels decreased more in the HIVC group compared to standard care alone. Multiple regression analysis showed HIVC treatment was independently associated with greater reductions in hs-CRP, IL-6, and TNF-⍺. See also Xia.
Xia et al., 30 Nov 2021, retrospective, China, peer-reviewed, 5 authors, study period 1 February, 2020 - 10 March, 2020. Contact:
This PaperVitamin CAll
High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019
Guozhi Xia, Di Fan, Yanru He, Yaohu Zhu, Ph.D Qiangsun Zheng
Nutrition, doi:10.1016/j.nut.2021.111405
High-dose intravenous vitamin C (HIVC) is a major concern when treating patients with coronavirus disease 2019 . The aim of this study was to assess the clinical efficacy of HIVC on hyperinflammation in patients with severe COVID-19. Methods: This retrospective cohort study included hospitalized patients with severe COVID-19, a subset of whom was treated with HIVC. The medical records were screened for demographic data, laboratory findings, and medications, as well as initial and repeated values of multiple inflammatory markers for analysis. Results: A high percentage of patients presented with hyperinflammation based on inflammatory marker levels above the upper limit of normal (high-sensitivity C-reactive protein, 80.1%; interleukin-6, 91.5%; and tumor necrosis factor-a, 67.4%). Eighty-five (36%) patients received HIVC therapy. After treatment with HIVC, the levels of inflammatory markers displayed a significant decrease compared with those of patients without HIVC. Furthermore, the percentages of reduction in inflammatory marker levels were higher in patients receiving HIVC compared with those in patients treated without HIVC. Stepwise multiple linear regression analysis revealed that HIVC was independently associated with percentages of reduction in levels of inflammatory markers. Conclusions: HIVC has the potential benefit of attenuating hyperinflammation by reducing inflammatory marker levels in patients with severe COVID-19.
Carr, Rosengrave, Bayer, Chambers, Mehrtens et al., Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes, Crit Care
Carr, Rowe, The emerging role of vitamin C in the prevention and treatment of COVID-19, Nutrients
Channappanavar, Perlman, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol
Chen, Luo, Yuan, Wang, Yang et al., Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages, Mediators Inflamm
Du, Yuan, Sun, Tang, Cheng et al., Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms, World J Gastroenterol
Fowler 3rd, Syed, Knowlson, Sculthorpe, Farthing et al., Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis, J Transl Med
Fowler Aa 3rd, Kim, Lepler, Malhotra, Debesa et al., Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome, World J Crit Care Med
Fowler Aa 3rd, Truwit, Hite, Morris, Dewilde et al., Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial, JAMA
Gao, Xu, Wang, Lv, Ma et al., The efficiency and safety of highdose vitamin C in patients with COVID-19: a retrospective cohort study, Aging
Gerlach, Gerlach, Markers of hyperinflammation, Minerva Anestesiol
H€ Artel, Strunk, Bucsky, Schultz, Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes, Cytokine
Lau, Lau, Chan, Li, Chen et al., Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment, J Gen Virol
Li, Geng, Peng, Meng, Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharm Anal
Lipworth, Chan, Lipworth, Kuo, Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection, J Allergy Clin Immunol Pract
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Moore, June, Cytokine release syndrome in severe COVID-19, Science
Mousavi, Bereswill, Heimesaat, Immunomodulatory and antimicrobial effects of vitamin C, Eur J Microbiol Immunol
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophsiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA
Xia, Ma, He, Wang, Zhu, Hyper-inflammatory response involves in cardiac injury among patients with coronavirus disease
Zhang, Rao, Li, Zhu, Liu et al., Pilot trial of high-dose vitamin C in critically ill COVID-19 patients, Ann Intensive Care
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop